Drug Trial Radar · NCT05409326
A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects
Last checked: Nov 20, 2026Latest source record: Jun 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
48
Planned (sponsor's estimate)
Start
Jun 2022
Primary completion
Jun 2023
Study completion Aug 2023
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled trial design was used to assess the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics, and immunogenicity of TQH2722 injection in healthy subjects.
Conditions
- Atopic Dermatitis
Interventions
TQH2722 injectionDrug
TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
Placebo to match TQH2722Drug
TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AE)Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- Serious adverse events (SAE)Time frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- Blood biochemistryTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- Coagulation functionTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- Blood routineTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- UrinalysisTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- Blood pressureTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- PulseTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- Body temperatureTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- SkinTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- Mucous membranesTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- Lymph nodesTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- HeadTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- NeckTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- ChestTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- AbdomenTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- SpineTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- LimbsTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
- 12-lead electrocardiogramTime frame: From the date of randomization until the date of withdrawal from the clinical trial for any reason, assessed up to 99 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.